Research Paper Volume 15, Issue 24 pp 15419—15433
Clinical value of SLC12A9 for diagnosis and prognosis in colorectal cancer
Figure 3. The meta-analysis of SLC12A9 in multiple cohorts. (A) Meta analysis result. Heterogeneity test. I2 = 68.6%. The results showed the high expression of SLC12A9 in colorectal cancer (SMD = 1.42, CI: 1.26-1.59). (B) Results of meta analysis after omitting. (C) sROC analysis. (D) Fagan’s diagram. (E) sROC analysis. (F) Detection of publication bias.